Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Heart Failure: a EMPEROR Validation Cohort

In this episode, Dr. Valentin Fuster discusses groundbreaking research on SGLT2 inhibitors and their impact on heart failure, highlighting the validation of mechanistic proteomic signatures from a major clinical trial. The study reveals how empagliflozin influences over 2,000 proteins, promoting autophagy, enhancing mitochondrial health, and normalizing kidney function, offering new insights into therapeutic strategies for heart failure management.

Om Podcasten

Each week, Valentin Fuster, MD, PhD, MACC, records free podcasts highlighting journal findings. To keep clinicians updated on the most important science emerging in clinical and translational cardiology, Dr. Fuster provides an overview of the weekly edition from the Journal of the American College of Cardiology (JACC), as well as a short summary of each manuscript. Encompassing JACC and nine cardiovascular specialty journals, the JACC family of journals rank among the top cardiovascular peer-reviewed journals in the world for scientific impact.